Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.75 6.25% 12.75 717,109 10:10:20
Bid Price Offer Price High Price Low Price Open Price
12.50 13.00 12.75 12.25 12.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 31.00 0.23 -0.01 86
Last Trade Time Trade Type Trade Size Trade Price Currency
11:25:18 O 9,220 12.75 GBX

Open Orphan (ORPH) Latest News

More Open Orphan News
Open Orphan Investors    Open Orphan Takeover Rumours

Open Orphan (ORPH) Discussions and Chat

Open Orphan Forums and Chat

Date Time Title Posts
07/7/202210:56Open Orphan - Big things to come4,467
22/2/202209:13open orphan a new beginning 20,223
17/1/202221:37Open Orphan with charts 202219

Add a New Thread

Open Orphan (ORPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Open Orphan trades in real-time

Open Orphan (ORPH) Top Chat Posts

Open Orphan Daily Update: Open Orphan Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ORPH. The last closing price for Open Orphan was 12p.
Open Orphan Plc has a 4 week average price of 10.72p and a 12 week average price of 10.72p.
The 1 year high share price is 27.50p while the 1 year low share price is currently 10.72p.
There are currently 670,929,314 shares in issue and the average daily traded volume is 3,085,627 shares. The market capitalisation of Open Orphan Plc is £85,543,487.54.
m5: Here you go. "Open Orphan" or the "Company") GBP14.7m influenza contract signed Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan plc, has signed a GBP14.7m contract for an influenza characterisation study and a follow on influenza human challenge study with an existing top five global pharmaceutical client. Revenue from the contract will be recognised across 2022 and 2023. This follows a challenge virus manufacturing contract signed with the same client, announced on 4 May 2022. Following completion of the challenge agent manufacturing, the characterisation study will identify a dose of the flu challenge agent that causes a safe and reliable infection in healthy volunteers. The study, which is sponsored by hVIVO, is expected to start in Q3 2022, subject to the relevant regulatory approvals, and will enrol volunteers recruited from the Company's clinical trial volunteer recruitment arm, FluCamp . As part of the study, hVIVO Labs will develop and validate challenge agent specific assays for the new flu challenge agent to US Food and Drug Administration (FDA), European Medicines Agency (EMA) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) standards. This includes quantitative polymerase chain reaction (qPCR) for viral load determination, viral infectivity assay and serological assays for antibody level determination. Following completion of the characterisation study, hVIVO will conduct a human challenge study, expected to commence in Q1 2023. The study will enable the Company to determine the efficacy of a number of different vaccine candidates for the reduction in incidence of symptomatic flu infection and disease severity in healthy volunteers. This will help select which of the candidates to progress further into later stage clinical trials. The vaccine study can be initiated, subject to receipt of the relevant regulatory approvals, as soon as the Company completes the infectivity and safety data review from the characterisation study and establishes the best challenge agent dose for safe volunteer inoculation. Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said: "This is another important milestone for hVIVO in that, in addition to the previously announced manufacture of a bespoke challenge agent, we have now been contracted to conduct the characterisation and the challenge studies with this big pharma customer. Moreover, we will also be providing full recruitment and laboratory services. This highlights hVIVO's unique full-service offering in running complex human challenge studies. Our team has a long history of manufacturing challenge agents and conducting human challenge studies. In regard to challenge studies our experience is unrivalled, our scientific expertise unmatched, and our operational delivery in a class of its own." Alex Mann, Senior Director of Clinical Science of hVIVO, Sponsor Representative and Scientific Design Lead, commented: "This major contract win solidifies hVIVO's position in the market in offering the full spectrum of support to clients, from start to finish of the vaccine and drug discovery process. Furthermore, the development of challenge agent specific assays underlines the skill and expertise of our experienced lab scientific team to validate bespoke assays to international standards for use in good clinical practice (GCP) clinical trials. The threat of influenza has never been greater, with an estimated one billion cases per year. Our continued work to support our clients' vaccine and antiviral programme's will support the quick, efficient and cost-effective development of these lifesaving medicines."
horsefeathers: Shandy - not deramping, just trying to inject some honesty (I would have thought ORPH investors would welcome this under the circumstances) about what is really happening and why the share price is doing what it is. The announcements and hype and ramping and big talk are all fine, but haven't we heard all that before? I am simply suggesting that the market has had enough of it, and puts it into the "Jam Tomorrow" bucket. The market is in "seeing is believing" mode on ORPH. Show us the money. If they announced the H1 2022 numbers (ON TIME for a change - not dragging it out until the last minute) and they said that revenues are £25m for H1 and EBITDA is £2.5m (without any funnies included), then the current price might be justified. In the meantime, the share price will drift downwards.
sikhthetech: shandy "Firstly, cash could not be announced yesterday and you know it. " That's BS and you know it. They are 3 weeks away from H1 end. They published other figures, like contracts signed but selected not to publish the most important figure, the current cash balance. That raises questions as to why are they hiding their current cash balance? "As at 1 June 2022, Open Orphan had an order book of signed contracts worth GBP64.2m which is expected to be recognised across 2022, 2023 and 2024." They had no problem publishing their current(as of 31st May) cash balance when they announced their fy2020 results on 17th June 2021. "Cash and cash equivalents of GBP15.1m as at 31 May 2021 " I'm sure some gullible readers will be swayed by your BS. I'm certain your mates will vote your post up without bothering to check the facts.. ;-) Honest guv.
judijudi: Missed promises always come back to bite a CEO and as a direct result this hits the share price He’s got a fair back catalogue of failed targets and broken “I wills” As well as the infamous “We will double the share price every 6 months” and after saying the share price was over valued imho
garth: Stock Box video above has ORPH share price listed at 82p on the video banner line... I'll take that for a target :0) G.
garth: If we were look at a 3x revenue rating that would be in excess of 6p on the share price right there... Whatever way you slice it - its worth enough pennies on the share price to take us well clear of that year long down trend. Just a view. G.
atlantic57: I continue to struggle to understand the share price performance. The business appears to be doing outstandingly well with substantial cash . Yet the share price continues to go no where . I can't explain it
sikhthetech: taylor, Come on then...your turn.. TLY have done exactly what they said they would, ie grow a diversified business. What about Orph/Polb??? Why haven't Orph spun off DiM by end of 2021? Why hasn't DiM any contracts? Why isn't the share price doubling every 6 months? Why are PIs selling their Polb specie shares as soon as they receive them and so there's no strong shareholder strong shareholder support?? Polb down to 4.5p, over 50% below the IPO.. Lot of questions with this, don't you think??
burtond1: Open Orphan's pipeline at the highest its ever been says @TMSreach "...It's only a matter of time before the @OpenOrphan share price goes up..."Here, #ORPH CEO Mo Khan catches up with @copytaster and explains why he is so confidence on the companies growth potential.
bobsworth: £60m of signed contracts in the bag yet some shareholders remain pessimistic !?!?! - Very Odd!!!! Open Orphan Plc Signs Fourth Contract in 2022 🐝Small Company Champion 📈 May 5 By Elric Langton | 5 May 2022 I have a financial interest in Open Orphan hVIVO, a subsidiary of Open Orphan Plc (AIM: ORPH) rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials (truly is - it is not a myth), has been awarded a new study with an existing Big Pharma client to act as a vaccination site for a Phase II field study of the client’s respiratory syncytial virus (RSV) vaccine candidate. This is the second contract in as many days and represents four this year, including a substantial contract with an existing top 5 global pharmaceutical client to manufacture a virus for use in human challenge studies and a £5m RSV human challenge study contract with a European biotechnology company. If investors were to take their leed from the share price, they would be forgiven for thinking the Company has been exceptionally quiet on the contract front and lacking news offering guidance for the future of the Company. Yet, it is entirely the opposite. In addition, the four contracts further boost the FY 2022 forecast, which appears to be closer to £60 million in total than the forecast of £50 million. I wonder why so many investors are so pessimistic - the management is delivering revenue-bearing contracts and offering a broader cross-selling opportunity. Also, this year, Open Orphan had a COVID-19 Characterisation Study peer-reviewed results published in the industry-leading periodical Nature Medicine. This opens the door for significant COVID-19 challenge studies. FDA Breakthrough Designation for Big Pharma RSV candidate - Vaccine candidate assessed in successful human challenge trial conducted by hVIVO, a subsidiary of Open Orphan, completed a Phase 2, double-blinded, placebo-controlled human challenge trial to assess MVA-BN® RSV using its RSV Human Challenge Study Model. A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines intended to treat a serious condition. Anyway, today’s contract is a significant award for Open Orphan as it is the first study as a vaccination site and the first contract since the enlarged product offering following the facilities expansion at Plumbers Row in March and provides validation of the Company’s strategy to offer complementary services to its clients outside of our traditional human challenge trial expertise. These additional services provide cross-selling opportunities for the Company. Still, as they utilise existing staff, facilities, and expertise, they come at a lower cost, increasing gross margin because we do not need to hire any additional staff or resources to run these studies. RNS As part of the study, hVIVO will recruit 60 healthy volunteers to the Company's new site clinic at Plumbers Row. They will then be inoculated with either the RSV vaccine candidate or a placebo. As opposed to a human challenge study, where volunteers would then be challenged and quarantined within hVIVO's FluCamp facilities, these participants will then be free to leave the facilities. Participants will then be monitored for RSV symptoms over the following months, with regular clinical check-ups at Plumbers Row, to assess the vaccine candidate's efficacy and its ability to prevent illness through RSV. The study is expected to begin in Q3 2022, with the majority of revenue from the contract recognised in 2023. This is the first vaccine field study the Company has been awarded since it announced the expansion of its facilities on 8 March 2022. In addition to the core human challenge studies, the expansion has enabled Open Orphan to provide a more extensive service offering, including non-first in human Phase I trials such as PK (pharmacokinetics) studies, bridging studies and Phase II trials in patients and healthy volunteers. The volunteers for the study will be recruited through the Company's specialist volunteer recruitment arm, FluCamp. FluCamp has decades of experience attracting suitable healthy subjects to meet recruitment requirements, primarily sourcing subjects for hVIVO trials to date. In addition, FluCamp's large database, tech-enabled platform and recently improved screening capabilities will mean that hVIVO is able to efficiently recruit and assess potential volunteers for its client's field studies in a timely and cost-effective manner. Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said: “This is a significant award for Open Orphan as it is our first study as a site. To date, we have mainly acted as a Contract Research Organisation to provide either challenge studies, laboratory or consulting services. Although we have acted as a site as part of the challenge studies, we have not provided stand-alone site services. We expanded our facilities at Plumbers Row in March of this year with the aim to provide site services. It is a great testament to the team that they have been able to fulfil site activity work in such a short timeframe. There are a great number of synergies between our core challenge study activities and new site services, this will help us to conduct the new work in an efficient manner.” Subscribe to 📈Small Company Cham
Open Orphan share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220707 10:57:03